Northpointe Bancshares, Inc.

NYSE:NPB

Banks - Regional

Financial Services
$14.79 +0.11%

+$0.02 today

Market cap
$511.47M
Beta
0.11
P/E (TTM)
3.1
EPS (TTM)
$5.85
Dividend yield
0.56%
52W Low $12.95High $19.48

Volume 0.33M

Average 0.15M

NPB Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Northpointe Bancshares, Inc.NYSE: NPB

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $64.05M rose 23.2% year over year, behind the +29.0% change in trailing-twelve-month gross profit. Sequentially, it fell 2.7% from the prior quarter. Over 3 fiscal years it compounded at -2.1% a year.

Context

  • Gross profit amounted to 50.9% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +23.2% toward the trailing-twelve-month pace of +29.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$64.05M-2.7% QoQ
Last fiscal yearDec 2025
$239.62M+27.8% YoY
LTMMar 2026
$251.77M+29.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.2%——
1 year+27.8%——
3-year CAGR-2.1%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
239.62M USD
Year-over-year change
+27.8%
4-year CAGR
+291.1%

Gross Profit vs competitors

How NPB compares with its peers on the latest reported figures

  • NPB's LTM Mar 2026 gross profit of $251.77M is the 3rd highest of the 7 companies compared; the peer median is $16.49M.
  • Its year-over-year change of +29.0% is the 3rd highest of 7, against a peer median of -2.6%.
  • Gross profit amounts to 51.1% of revenue for NPB, versus a peer median of 57.0%.
NPB Competitors Peer median
Gross Profit for NPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$774.12M +40.6%+129.1%57.0%
ZLABZai Lab LimitedLTM Jun 2026$253.9M -4.9%+24.0%56.5%
NPBNorthpointe Bancshares, Inc.LTM Mar 2026$251.77M +29.0%-2.1%51.1%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$33.06M -2.5%-3.5%94.8%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$79K -2.6%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$150K +31.8%——
ERASErasca, Inc.LTM Sep 2026-$1.47M -76.2%——
Peer median (excluding NPB) $16.49M-2.6%+24.0%57.0%

Competitors are the stored peer set for NPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.17M324.24M362.45M390.46M471.18M
Cost of Revenue1.14M68.9M164.68M202.99M231.56M
Gross Profit1.02M255.34M197.77M187.47M239.62M
Gross Margin47.3%78.7%54.6%48.0%50.9%
Research & Development29.88M0000
Selling, General & Admin22.17M159.88M104.29M77.79M93.62M
Operating Expenses52.05M221.65M153.08M114.59M129.23M
Depreciation & Amortization840.94K4.02M4.02M3.8M3.07M
EBITDA(56.67M)37.71M48.7M76.68M113.47M
EBITDA Margin-2613.5%11.6%13.4%19.6%24.1%
Operating Income(51.03M)33.69M44.69M72.88M110.39M
Operating Margin-2353.1%10.4%12.3%18.7%23.4%
Interest Income525.54K166.12M267.38M317.53M380.2M
Interest Expense066.69M166.16M203.32M229.47M
Other Income / Expenses(6.49M)0000
Income Before Tax(57.52M)33.69M44.69M72.88M110.39M
Pre-Tax Margin-2652.3%10.4%12.3%18.7%23.4%
Income Tax Expense(77.7K)10.46M10.93M17.72M26.98M
Net Income(57.44M)23.24M33.76M55.16M83.41M
Net Margin-2648.7%7.2%9.3%14.1%17.7%
EPS (Basic)(1.74)0.921.613.154.92
EPS (Diluted)(1.74)0.921.613.154.85
Weighted Avg Shares33.03M14.92M14.92M14.92M14.54M
Weighted Avg Shares (Diluted)33.03M14.92M14.92M14.92M14.72M

Northpointe Bancshares, Inc.

NYSE:NPB

Intrinsic Alpha fair value

Locked

Current Price

$14.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.